ESMO 2024 Highlights Webinar-ESMO 2024 Highlights Webinar

Video Transcription

Video Summary

The ESLC webinar "ESMO 2024 Highlights" covers recent advancements in lung cancer treatment, focusing on both non-small cell lung cancer (NSCLC) and small cell lung cancer. Dr. Michele Aldea and Francesco Pasiglia led discussions on emerging research, trials, and treatment regimens presented at ESMO 2024.<br /><br />Dr. Silvia Novello presented on early-stage NSCLC, including insights into adjuvant, neoadjuvant, and perioperative settings. She emphasized the need for biomarker-driven studies to pinpoint patients who would benefit from neoadjuvant chemotherapy-free immunotherapy.<br /><br />Professor Benjamin Best discussed metastatic NSCLC, highlighting recent trials for innovative therapies, including those targeting EGFR mutations, ALK inhibitors, and ROS1-positive cancers. He stressed the need for combining molecular and PD-L1 status to determine treatment paths and discussed challenges with new antibody-drug conjugates.<br /><br />Dr. Ross Soh focused on small cell lung cancer and thymic epithelial tumors, examining trials like Adriatic and therapies combining pembrolizumab with lenvatinib, which showed promise in progression-free survival among certain cancer types.<br /><br />The webinar concluded with a Q&A, addressing questions about the future of lung cancer treatments and strategies for patients with rare driver mutations or those relapsing after standard regimens.

Meta Tag

Concept Early-Stage Non-Small Cell Lung Cancer

Concept Metastatic Non-Small Cell Lung Cancer

Concept Small Cell Lung Cancer

Concept Adjuvant Therapy

Concept Neoadjuvant Therapy

Keywords

ESMO 2024 Highlights

lung cancer treatment

NSCLC

small cell lung cancer

biomarker-driven studies

EGFR mutations

antibody-drug conjugates

pembrolizumab lenvatinib

rare driver mutations

Early-Stage Non-Small Cell Lung Cancer

Metastatic Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Adjuvant Therapy

Neoadjuvant Therapy